Cybin Inc./$HELP
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Cybin Inc.
Helus Pharma Inc is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways associated with neuroplasticity. These compounds are being investigated for potential use in the treatment of depression, anxiety, and other mental health conditions, areas where there is an unmet medical need. It aims to provide treatments designed for mental health disorders. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of substantial depressive disorder. It operates in Canada, the United States, the United Kingdom, and Ireland.
Ticker
$HELP
Sector
Primary listing
Employees
50
Headquarters
Toronto, Canada
Website
Cybin Inc. Metrics
BasicAdvanced
$376M
-
-$3.97
1.08
-
Price and volume
Market cap
$376M
Beta
1.08
52-week high
$9.83
52-week low
$4.81
Average daily volume
821K
Financial strength
Current ratio
8.575
Quick ratio
6.622
Long term debt to equity
20.783
Total debt to equity
20.783
Interest coverage (TTM)
-33.85%
Profitability
EBITDA (TTM)
-98.725
Management effectiveness
Return on assets (TTM)
-32.87%
Return on equity (TTM)
-52.96%
Valuation
Price to book
1.41
Price to tangible book (TTM)
2.71
Price to free cash flow (TTM)
-1.657
Free cash flow yield (TTM)
-60.35%
Free cash flow per share (TTM)
-4.544
Growth
Earnings per share change (TTM)
-32.91%
3-year earnings per share growth (CAGR)
-24.06%
Cybin Inc. News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cybin Inc. stock?
Cybin Inc. (HELP) has a market cap of $376M as of January 11, 2026.
What is the P/E ratio for Cybin Inc. stock?
The price to earnings (P/E) ratio for Cybin Inc. (HELP) stock is 0 as of January 11, 2026.
Does Cybin Inc. stock pay dividends?
No, Cybin Inc. (HELP) stock does not pay dividends to its shareholders as of January 11, 2026.
When is the next Cybin Inc. dividend payment date?
Cybin Inc. (HELP) stock does not pay dividends to its shareholders.
What is the beta indicator for Cybin Inc.?
Cybin Inc. (HELP) has a beta rating of 1.08. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.